Print this page    •   Back to Web version of article

U.S. News
amfAR National HIV/AIDS Update Conference Focuses Attention on Epidemic Among Minorities, Women

April 13, 2005

The American Foundation for AIDS Research in Oakland, Calif., on Sunday began its four-day, 17th annual National HIV/AIDS Update Conference, which aims to focus attention on the epidemic among African Americans, Latinos, and women and girls, populations that comprise the "new face of HIV/AIDS," the Pleasanton Tri-Valley Herald reports. In the keynote address to about 2,000 HIV/AIDS researchers and advocates at the conference, Rep. Barbara Lee (D-Calif.) emphasized the need to examine "underlying factors," such as poverty, that might cause some communities to be "more vulnerable" to HIV/AIDS, according to the Herald (Vesely, Pleasanton Tri-Valley Herald, 4/12). "When we talk about AIDS prevention, we must also talk about the socio-economic environment in our country -- such as ending poverty, unemployment, homelessness, hunger, stigma, discrimination, ignorance and inequality -- in the same breath," Lee said, adding, "The sooner that we help the public and policymakers understand that HIV/AIDS is thriving in underserved communities because [of] neglect, homophobia and racism, the sooner we can get government to fight on our side against these inequalities" (Lee release, 4/11). A mistrust of the health care system and unequal access to new antiretroviral drug treatments also are "major" problems in addressing the HIV/AIDS epidemic in African-American communities, Dr. William King, director of the Clinical AIDS Research & Education Center at the University of California-Los Angeles, said at the conference (Pleasanton Tri-Valley Herald, 4/12).

amfAR Survey
A survey commissioned by amfAR and presented at the conference showed that HIV/AIDS patients with previous failure to respond to at least two antiretroviral regimens still have "high standards" for treatment success and need to discuss their treatment goals with physicians in order to find an appropriate drug therapy, according to an amfAR release. The survey -- which was conducted by Harris Interactive from Jan. 5 through Feb. 18 -- included 150 HIV/AIDS doctors who had been practicing for at least three years. The doctors recruited 115 HIV/AIDS patients ages 18 and older who took two or more antiretroviral drug combination therapies. The survey found that:

The survey was conducted with support from the pharmaceutical companies Roche and Trimeris (amfAR release, 4/11). Trimeris and Roche jointly developed Fuzeon, an injectable antiretroviral that is in a class of drugs called fusion inhibitors and designed for HIV/AIDS patients who have failed to respond to other medications (Kaiser Daily HIV/AIDS Report, 3/14).

Webcasts of select sessions of the conference are available online from's HealthCast.

Back to other news for April 13, 2005

Reprinted with permission from You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at The Kaiser Daily HIV/AIDS Report is published for, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.